This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John A. Colwell, MD, PhD

JAMA. 1997;278(20):1700.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Ever since the publication of the Diabetes Control and Complications Trial,¹ health care professionals, people with diabetes, administrators, and governmental agencies have been concerned about translation of the findings into clinical practice. The study showed that an intensive approach to glycemic regulation, which entailed frequent visits and contact with a health care team, can produce a significant improvement in hemoglobin A1c (HbA_1c) levels in people with type 1 diabetes, and can lower the risk for progression of retinopathy from 50% to 75%, depending on the end points chosen. In addition, significant lowering of the risk for progression of albuminuria and sensory neuropathy was achieved. Some of the major issues have been:

1. Should these results be applied to people with type 2 diabetes?

2. What are the guidelines for levels of HbA_1c that should lead to action, and what is the target level to achieve?

3. Can . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, Medical University of South Carolina, Charleston.

Footnotes
Reprints: John A. Colwell, MD, PhD, E210K, Clinical Sciences Building, Medical University of South Carolina, Charleston, SC 29425 (e-mail: colwelja@musc.edu).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?